The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescent
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
MK-3475-667: An Open-label, Uncontrolled, Mul
To learn more about available lymphoma clinical trials, contact us at email@example.com or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2019 Cincinnati Children's Hospital Medical Center. All rights reserved.